for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ekso Bionics Holdings Inc

EKSO.O

Latest Trade

3.90USD

Change

-0.17(-4.18%)

Volume

127,315

Today's Range

3.88

 - 

4.08

52 Week Range

3.88

 - 

14.98

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.07
Open
4.08
Volume
127,315
3M AVG Volume
2.24
Today's High
4.08
Today's Low
3.88
52 Week High
14.98
52 Week Low
3.88
Shares Out (MIL)
12.66
Market Cap (MIL)
51.51
Forward P/E
-3.88
Dividend (Yield %)
--

Next Event

Q3 2021 Ekso Bionics Holdings Inc Earnings Release

Latest Developments

More

Ekso Bionics Reports Second Quarter 2021 Results

Ekso Bionics Reports Q4 And Year End 2020 Results

Ekso Bionics Announces $10 Million Bought Deal Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ekso Bionics Holdings Inc

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products that augment human strength, endurance and mobility. The Company’s exoskeleton technology serves multiple markets and can be utilized both by able-bodied users and persons with physical disabilities. The Company operates through two segments: EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, sells and rents exoskeletons for applications in the medical markets. Its leading product in EksoHealth, the EksoNR, is a robotic exoskeleton used to provide physical therapy for patients with lower extremity impairment. EksoWorks segment designs, engineers, manufactures, sells, and rents exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. Its products include EksoZeroG Arm and and EksoVest. EksoZeroG Arm is a mobile arm mount and EksoVest is an upper body exoskeleton.

Industry

Medical Equipment & Supplies

Contact Info

1414 Harbour Way S Ste 1201

RICHMOND, CA

94804-3628

United States

+1.510.9841761

https://ir.eksobionics.com/

Executive Leadership

Steven A. Sherman

Executive Chairman of the Board

Jack Peurach

President, Chief Executive Officer, Director

John F. Glenn

Chief Financial Officer, Secretary

Jason C. Jones

Vice-President of Product Development

William R. Shaw

Chief Commercial Officer

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-6.900

2019

-2.550

2020

-2.210

2021(E)

-1.050
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.56
Price To Book (MRQ)
1.28
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
4.97
LT Debt To Equity (MRQ)
4.97
Return on Investment (TTM)
-20.36
Return on Equity (TTM)
-17.17

Latest News

Latest News

BRIEF-Ekso Bionics Gets FDA Clearance To Market Eksonr Robotic Exoskeleton

* EKSO BIONICS® RECEIVES FDA CLEARANCE TO MARKET ITS EKSONR™ ROBOTIC EXOSKELETON FOR USE WITH ACQUIRED BRAIN INJURY PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Ekso Bionics Holdings Files For Mixed Shelf Of Upto $75 Mln

* EKSO BIONICS HOLDINGS INC FILES FOR MIXED SHELF OF UPTO $75 MILLION - SEC FILING Source: (https://bit.ly/2YIlMgb) Further company coverage:

BRIEF-Ekso Bionics Announces $7.89 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

* EKSO BIONICS ANNOUNCES $7.89 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

BRIEF-Ekso Bionics Announces CFIUS Determination Regarding China Joint Venture

* EKSO BIONICS ANNOUNCES CFIUS DETERMINATION REGARDING CHINA JOINT VENTURE

BRIEF-Ekso Bionics To Reduce Workforce By Approximately 35%

* EKSO BIONICS HOLDINGS INC - IMPLEMENTED A PLAN TO REDUCE ITS WORKFORCE BY APPROXIMATELY 35%

BRIEF-Ekso Bionics Holdings - Entered Into An Unsecured Note Evidencing A $1.1 Mln Unsecured Loan

* EKSO BIONICS HOLDINGS - ENTERED INTO AN UNSECURED NOTE EVIDENCING AN UNSECURED LOAN IN AMOUNT OF $1.1 MILLION UNDER PAYCHECK PROTECTION PROGRAM Source text: (https://bit.ly/354Dc9F) Further company coverage:

BRIEF-Ekso Bionics To Report Q1 Financial Results On April 30

* EKSO BIONICS® TO REPORT FIRST QUARTER 2020 FINANCIAL RESULTS ON APRIL 30, 2020 Source text for Eikon: Further company coverage:

BRIEF-Ekso Bionics Says COVID-19 Has Caused Order Delays

* EKSO BIONICS PROVIDES COVID-19 BUSINESS UPDATE AND REPORTS PRELIMINARY FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Ekso Bionics® Announces Reverse Stock Split

* EKSO BIONICS HOLDINGS INC - WILL EFFECT A REVERSE STOCK SPLIT OF SHARES OF ITS COMMON STOCK AT A RATIO OF 1-FOR-15 Source text for Eikon: Further company coverage:

BRIEF-Ekso Bionics Stockholders Approve Reverse Stock Split

* EKSO BIONICS HOLDINGS - STOCKHOLDERS APPROVED REVERSE STOCK SPLIT OF CO'S COMMON STOCK AT RATIO OF NOT LESS THAN 1-FOR-5 & NOT MORE THAN 1-FOR-15 Source text: (http://bit.ly/38ZPPmK) Further company coverage:

BRIEF-Puissance Cross-Border Opportunities Reports A Stake Of 13.3% In Ekso Bionics

* PUISSANCE CROSS-BORDER OPPORTUNITIES II LLC REPORTS A STAKE OF 13.3% IN EKSO BIONICS HOLDINGS INC AS OF MAR 4 - SEC FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up